|
July 11, 2022
|
Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022
|
|
|
June 17, 2022
|
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
|
|
|
June 2, 2022
|
Connect Biopharma to Participate at the Jefferies Healthcare Conference
|
|
|
May 17, 2022
|
Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference
|
|
|
May 3, 2022
|
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
|
|
|
March 31, 2022
|
Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update
|
|
|
March 1, 2022
|
Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer
|
|
|
February 9, 2022
|
Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
|
|
|
January 24, 2022
|
Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference
|
|
|
January 5, 2022
|
Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis
|
|
